肾衰宁颗粒联合前列地尔治疗慢性肾衰竭的临床效果及安全性  

Clinical effect and safety of Shenshuaining granules combined with alprostadil in the treatment of chronic renal failure

作　　者：杨亮 谭小猛 赵锋 YANG Liang;TAN Xiaomeng;ZHAO Feng(Qishan County Hospital,Baoji 722400;Xi'an International Medical Center Hospital,Xi'an 710100;Baoji High-tech Hospital,Baoji 721000,China)

机构地区：[1]岐山县医院,陕西宝鸡722400 [2]西安国际医学中心医院,陕西西安710100 [3]宝鸡高新医院,陕西宝鸡721000

出　　处：《临床医学研究与实践》2023年第1期124-127,共4页Clinical Research and Practice

摘　　要：目的探讨肾衰宁颗粒联合前列地尔治疗慢性肾衰竭的临床效果及安全性。方法选取我院2018年9月至2020年5月收治的92例慢性肾衰竭患者作为研究对象,按随机数字表法将其分为研究(1)组(n=46)和研究(2)组(n=46)。研究(1)组单纯接受前列地尔注射液治疗,研究(2)组在研究(1)组基础上给予肾衰宁颗粒治疗,两组均连续治疗3周。比较两组治疗3周后的临床病情控制情况;比较两组治疗前、治疗3周后的甲状旁腺素(PTH)、同型半胱氨酸(Hcy)水平、慢性肾衰竭生命质量量表(QLICD-CRF2.0)评分及药物不良反应(胸闷、头晕头痛、腹胀、便秘、食欲不振)发生情况。结果治疗3周后,研究(2)组的临床病情控制有效率为91.30%,高于研究(1)组的71.74%,差异具有统计学意义(P<0.05)。治疗前,两组的PTH、Hcy水平比较,差异无统计学意义(P>0.05);治疗3周后,两组的PTH、Hcy水平均降低,且研究(2)组低于研究(1)组,差异具有统计学意义(P<0.05)。治疗前,两组的QLICD-CRF2.0评分比较,差异无统计学意义(P>0.05);治疗3周后,两组的共性模块评分均升高,特异性模块评分均降低,差异具有统计学意义(P<0.05);治疗3周后,研究(2)组的共性模块评分高于研究(1)组,特异性模块评分低于研究(1)组,差异具有统计学意义(P<0.05)。治疗3周后,两组的药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论肾衰宁颗粒联合前列地尔治疗慢性肾衰竭的临床效果显著,可有效控制病情,降低PTH、Hcy水平,提高患者的生命质量,且安全性高,值得临床进一步推广。Objective To investigate the clinical effect and safety of Shenshuaining granules combined with alprostadil in the treatment of chronic renal failure.Methods A total of 92 patients with chronic renal failure admitted in our hospital from September 2018 to May 2020 were selected as the research objects,and the patients were divided into(1)study group(n=46)and(2)study group(n=46)according to the random number table method.The(1)study group was treated with alprostadil injection alone,and the(2)study group was treated with Shenshuanning granules on the basis of the(1)study group,both groups were treated continuously for 3 weeks.The clinical condition control was compared between the two groups after 3 weeks of treatment;the levels of parathyroid hormone(PTH)and homocysteine(Hcy),the scores of Quality of Life Instruments for Chronic Diseases-Chronic Renal Failure Scale 2.0(QLICD-CRF2.0)and the adverse drug reactions(chest tightness,dizziness and headache,abdominal distension,constipation and anorexia)were compared between the two groups before and after 3 weeks of treatment.Results After 3 weeks of treatment,the effective rate of clinical condition control in the(2)study group was 91.30%,which was higher than 71.74%in the(1)study group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of PTH and Hcy between the two groups(P>0.05);after 3 weeks of treatment,the levels of PTH and Hcy in the two groups decreased,and those in the(2)study group were lower than the(1)study group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the QLICD-CRF2.0 scores between the two groups(P>0.05);after3 weeks of treatment,the common module score in the two groups increased,while the specific module score decreased,and the differences were statistically significant(P<0.05);after 3 weeks of treatment,the common module score in the(2)study group was higher than that in the(1)study group,and the speci

关 键 词：肾衰宁颗粒 前列地尔 慢性肾衰竭 

分 类 号：R285.5[医药卫生—中药学]